Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,661 to 1,680 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Carrier Frequency of Spinal Muscular Atrophy in a Large-scale Korean Population. | Ann Lab Med | 2020 | 32067433 | PubTator, text mining | PubMed |
| A native function for RAN translation and CGG repeats in regulating fragile X protein synthesis. | Nat Neurosci | 2020 | 32066985 | PubTator, text mining | PubMed |
| Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. | Genet Med | 2020 | 32066871 | PubTator, text mining | PubMed |
| Synaptotagmin 13 is neuroprotective across motor neuron diseases. | Acta Neuropathol | 2020 | 32065260 | PubTator, text mining | PubMed |
Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264. | J Neurochem | 2020 | 32056234 | PubTator, text mining | PubMed |
| A roadmap for neurodevelopmental disease modeling for non-stem cell biologists. | Stem Cells Transl Med | 2020 | 32052596 | PubTator, text mining | PubMed |
| Transmission characteristics of SMN from 227 spinal muscular atrophy core families in China. | J Hum Genet | 2020 | 32051521 | PubTator, text mining | PubMed |
| The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future. | Med Res Rev | 2020 | 32043626 | PubTator, text mining | PubMed |
| Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy. | Neurol Genet | 2020 | 32042914 | PubTator, text mining | PubMed |
| RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. | J Neuromuscul Dis | 2020 | 32039859 | PubTator, text mining | PubMed |
| Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. | J Cell Mol Med | 2020 | 32032473 | PubTator, text mining | PubMed |
| Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. | J Cachexia Sarcopenia Muscle | 2020 | 32031328 | PubTator, text mining | PubMed |
| Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage. | Sci Rep | 2020 | 32029882 | PubTator, text mining | PubMed |
The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: Observational study. | Medicine (Baltimore) | 2020 | 32011487 | PubTator, text mining | PubMed |
| Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2. | J Neuromuscul Dis | 2020 | 32007960 | PubTator, text mining | PubMed |
| Drug treatment for spinal muscular atrophy types II and III. | Cochrane Database Syst Rev | 2020 | 32006461 | PubTator, text mining | PubMed |
| Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next. | Annu Rev Genomics Hum Genet | 2020 | 32004094 | PubTator, text mining | PubMed |
| Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next. | Brain Res | 2020 | 32001243 | PubTator, text mining | PubMed |
| A highly sensitive and specific workflow for detecting rare copy-number variants from exome sequencing data. | Genome Med | 2020 | 32000839 | PubTator, text mining | PubMed |
| The prevalence of spinal muscular atrophy carrier in China: Evidences from epidemiological surveys. | Medicine (Baltimore) | 2020 | 32000428 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=84